(Q33711371)

English

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

Evan Gomes-Giacoia

1

1 reference

Europe PubMed Central

28 July 2017

Makito Miyake

2

1 reference

Europe PubMed Central

28 July 2017

Steve Goodison

3

1 reference

Europe PubMed Central

28 July 2017

Aravindhan Sriharan

4

1 reference

Europe PubMed Central

28 July 2017

Ge Zhang

5

1 reference

Europe PubMed Central

28 July 2017

Lijing You

6

1 reference

Europe PubMed Central

28 July 2017

Jack O Egan

7

1 reference

Europe PubMed Central

28 July 2017

Peter R Rhode

8

1 reference

Europe PubMed Central

28 July 2017

Alexander S Parker

9

1 reference

Europe PubMed Central

28 July 2017

Karl X Chai

10

1 reference

Europe PubMed Central

28 July 2017

Hing C Wong

11

1 reference

Europe PubMed Central

28 July 2017

Charles J Rosser

12

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

4 June 2014

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

9

1 reference

Europe PubMed Central

28 July 2017

6

1 reference

Europe PubMed Central

28 July 2017

e96705

1 reference

Europe PubMed Central

28 July 2017

copyright license

Creative Commons Attribution 4.0 International

4 June 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Bladder Cancer Immunotherapy: BCG and Beyond.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Lactobacilli secreting a tumor antigen and IL15 activates neutrophils and dendritic cells and generates cytotoxic T lymphocytes against cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Novel human interleukin-15 agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Biology and clinical relevance of granulysin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Molecular credentialing of rodent bladder carcinogenesis models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Twelve immunotherapy drugs that could cure cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guérin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Cancer gene therapy: 'delivery, delivery, delivery'

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Interleukin-2 and interleukin-15: immunotherapy for cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Internalization of bacille Calmette-Guerin by bladder tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

21 June 2018

Promotion of bladder cancer development and progression by androgen receptor signals.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096705

21 January 2018

Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096705

21 January 2018

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096705

21 January 2018

IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096705

21 January 2018

Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0096705

21 January 2018

DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and bacillus Calmette-Guérin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

30 October 2018

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

30 October 2018

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

30 October 2018

Stimulation and priming of human neutrophils by IL-1 alpha and IL-1 beta: complete inhibition by IL-1 receptor antagonist and no interaction with other cytokines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045574

30 October 2018

Urinary IL‐2 assay for monitoring intravesical bacillus Calmette‐Guérin response of superficial bladder cancer during induction course and maintenance therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promoting effects of intravesical instillation of saline on bladder lesion development in rats pretreated with N-butyl-N-(4-hydroxybutyl) nitrosamine are inhibited by bacillus Calmette-Guerin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24896845

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0096705

1 reference

Europe PubMed Central

28 July 2017

2014PLoSO...996705G

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33711371&oldid=1977228349"